<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

 

 

Pancreatic Cancer PDX Models
A Champions Model Cohort

A meticulously curated bank of Pancreatic Cancer PDX models, directly established from patient biopsies, featuring well-documented treatment histories, genomic mutations, and clinical characteristics. 

 

 

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

 

Champions' Advanced Pancreatic Cancer PDX Models

Champions Oncology offers 79* clinically relevant Pancreatic Cancer PDX models for oncology pharmacology studies and drug development, derived from late-stage, primary, and metastatic tumors, with many patients having received prior Standard of Care therapies. Most models have been characterized by Next Generation Sequencing (77* with WES, 74* with RNA-seq, and 72* with both) and in vivo drug response testing, providing a comprehensive dataset to evaluate biomarkers of response and non-response in pancreatic cancer. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)

Champions' leading Pancreatic Cancer PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Access to one of the largest  bank of pancreatic cancer PDX models with clinically relevant molecular
    and pathological characteristics on the market. 
  • Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
  • Includes models pretreated with advanced therapies like s erlotinib, 5 fluorouracil / irinotecan            / oxaliplatin combination therapy or gemcitabine/Nab-paclitaxel combination therapy.